Market Overview

Suono Bio Announces Strategic Investment by FUJIFILM Corporation


Company announces a strategic investment by FUJIFILM Corporation to
advance pipeline of novel treatments for inflammatory-mediated diseases

announced today a strategic investment by FUJIFILM Corporation
to advance Suono Bio's second-generation platform technology for the
ultra-rapid, formulation-independent administration of therapeutics
including biologics and gene therapies.

Suono Bio leverages technology developed in the laboratory of Institute
Professor Robert Langer at the Massachusetts Institute of Technology
(MIT) to facilitate rapid, local administration of therapeutics to treat
serious diseases. The company has demonstrated pre-clinical activity in
a range of diseases using a diverse set of therapeutics, including
genetic material, at clinically-relevant doses. The company was founded
by Professor Langer, Dr. Giovanni Traverso, a gastroenterologist and
biomedical engineer at Brigham and Women's Hospital, Harvard Medical
School, Amy Schulman, partner at Polaris Partners and executive chair of
Suono Bio, and Dr. Carl Schoellhammer, who also served as founding CEO.
In addition to Polaris Partners, Suono Bio is backed by MIT's The
Engine, a unique venture capital firm founded by MIT to invest in tough
tech companies, and MedTech Venture Partners, which funds and supports
medical technology entrepreneurs.

"I am thrilled that we have the opportunity to forge a long and fruitful
relationship with FUJIFILM to advance the development of our core
technology," said Dr. Schoellhammer. "Their investment is a critical
validation of our platform."

"FUJIFILM has deep technical expertise and offers the chance to
accelerate our development by working closely with their scientists and
engineers in the future," added Professor Langer.


Suono Bio is developing therapeutic products for inflammatory-mediated
diseases leveraging their ultra-rapid and formulation independent
delivery technology. Suono Bio's platform enables rapid, localized
delivery of small molecules, biologics, and nucleic acids and gene
therapies without the need for encapsulation of the therapeutic. For
more information, please visit


FUJIFILM Holdings Corporation, Tokyo, Japan, brings innovative solutions
to a broad range of global industries by leveraging its depth of
knowledge and fundamental technologies derived from photographic film.
Its proprietary core technologies contribute to the fields of
healthcare, graphic systems, highly functional materials, optical
devices, digital imaging and document products. These products and
services are based on its extensive portfolio of chemical, mechanical,
optical, electronic and imaging technologies. For the year ended March
31, 2018, the company had global revenues of $23.0 billion, at an
exchange rate of 106 yen to the dollar. Fujifilm is committed to
responsible environmental stewardship and good corporate citizenship.
For more information, please visit:

View Comments and Join the Discussion!